Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Zacks.com on MSN2d
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
3d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback